Stock listing
KLRA Stock Price, News, Filings & Events — Kailera Therapeutics, Inc.
Selected listing: KLRA · BOATS · USD · US
This page tracks Kailera Therapeutics, Inc.'s KLRA:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following KLRA:BOATS. KLRA:BOATS is the stock-level entry point for investors researching Kailera Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Kailera Therapeutics, Inc. (ticker: KLRA) is a public company based in the United States with a market capitalization of approximately $2.4 billion. The company focuses on developing innovative therapies to address unmet medical needs. Kailera is committed to advancing its research and development efforts to improve patient outcomes.

- Ticker
- KLRA:BOATS
- Asset type
- Stock
- Market cap
- $1.81B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
Kailera Therapeutics, Inc. KLRA:BOATS stock context
This page tracks Kailera Therapeutics, Inc.'s KLRA:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following KLRA:BOATS. KLRA:BOATS is the stock-level entry point for investors researching Kailera Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Kailera Therapeutics, Inc. (ticker: KLRA) is a public company based in the United States with a market capitalization of approximately $2.4 billion. The company focuses on developing innovative therapies to address unmet medical needs. Kailera is committed to advancing its research and development efforts to improve patient outcomes.
Latest news from Kailera Therapeutics, Inc.
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 12, 2026
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
August 11, 2026
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Recepto...
July 7, 2026
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
June 5, 2026
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Research Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for KLRA:BOATS.
Kailera Therapeutics, Inc. company profile
View the public company page for Kailera Therapeutics, Inc. on 6ix.
Kailera Therapeutics, Inc. news
Read company news and market updates connected to Kailera Therapeutics, Inc..
Kailera Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Kailera Therapeutics, Inc..